IGHG3 and Zika virus infectious disease: A total of 1,043 participants had previous ZIKV infection (anti-ZIKV IgG), yielding an overall weighted seroprevalence of 50.4% (95%CI: 47.2%-53.6%) (Fig 3, Table 2) and a sensitivity and specificity adjusted prevalence of ZIKV infection (anti-ZIKV NS1 IgG and/or IgG3) of 38.6% (95%CI: 22.8%-54.2%) (Table 3).